Marksans Pharma is a global generic pharmaceutical formulator that manufactures tablets, soft gels, and other dosage forms in India and sells them under OTC and prescription labels across North America, the UK and Europe, Australia and New Zealand, and rest of world. The company sits as a low-cost manufacturer supplying private label OTC products to major retailers in the US, where it is one of the top four players alongside Perrigo and others. In FY26, the company generated revenue of approximately INR 2,950 crores, with North America contributing 52% at INR 1,533 crores, and the UK and Europe adding INR 1,015 crores. EBITDA margin for FY26 was 20.4%, and Q1 FY27 came in at 25.3% before normalizing to the guided 20-21% for the full year, indicating a business that consistently earns above-average returns for a formulator.
The persistence of these economics rests on barriers that are not easily replicated. Regulatory approvals from the USFDA and MHRA, along with long-term customer contracts in the US private label OTC market, create switching costs for retailers who rely on Marksans for consistent supply. The company's two Goa facilities, including the unit acquired from Teva, have passed FDA inspections with zero Form 483 observations, and the Teva unit alone has capacity to support 40-50% more revenue from current utilization of around 50%. The product pipeline is deep: over 200 molecules are planned for filing in the UK over the next four years, and 51 additional products are in the US pipeline. This combination of compliance, cost advantage, and product breadth makes it difficult for new entrants to displace the company in its chosen niches.
The inflection point is now, as capacity and geographic expansion converge. The Teva facility is ramping from a revenue run-rate of INR 560-600 crores toward INR 800 crores, and the old plant's tablet capacity is expanding from 700-800 million to 1.2-1.3 billion tablets by end of 2026, with soft gel capacity tripling. In Europe, the acquisitions of Clinique BV (Netherlands) and ABC Now GmbH (Germany) closed in 2026, and Germany revenue is expected from early Q3 FY27, with Ireland following next fiscal year. The US order book stands at $220 million and is targeted to reach $300 million by FY28, while Australia is targeting $100 million in revenue within three years. By FY28, management expects revenue of INR 4,000 crores, up from approximately INR 2,950 crores in FY26, with EBITDA margin sustained at 20-21%.
Management's walk-talk has been mixed but is improving. They guided FY26 revenue of INR 3,000 crores but conceded in February 2026 they would be very close or maybe shy away from that figure, a miss of 3-4%. EBITDA margin guidance for FY26 was to maintain or improve on the prior year's 20.2%, but 9M FY26 came in at 19.4% before Q3 recovered to 21.3%. However, they have delivered on US growth (24% in FY26), completed two European acquisitions, and maintained a strong balance sheet with cash of INR 1,058 crores and net cash of INR 1,031 crores as of August 2026. They have reaffirmed FY27 guidance of 15-20% revenue growth and 20-21% EBITDA margin, and are evaluating two more European M&A targets with a view to closing in 2027.
The earnings path is visible: FY27 revenue should land between INR 3,400 and 3,540 crores, with EBITDA of INR 680-740 crores at the guided margin, and FY28 revenue of INR 4,000 crores implies EBITDA of INR 800-840 crores. For this to hold, the US order book must convert to revenue as planned, the Teva facility must reach higher utilization, and the European acquisitions must integrate without disruption. The single most important watchpoint is the ramp of the Teva facility and the conversion of the $220 million US order book, as these drive the operating leverage that underpins the margin guidance. A failure to achieve the 50% utilization milestone or a delay in European M&A would push the INR 4,000 crore target out, but the company's cash position and diversified geography provide a buffer.
companyname: Marksans Pharma Limited ticker: MARKSANS sector: Pharmaceuticals (Generic / OTC formulations) Marksans Pharma is a Mumbai-headquartered pharmaceutical company that develops, manufactures and distributes generic and over-the-counter (OTC) drugs across more than 60 countries. The company was incorporated in 1992 and spun off from Glenmark Pharmaceuticals in 2003. Its business model is built on manufacturing in low-cost Indian facilities and selling into regulated Western markets - th...
Read the full report →new product segment, geographic expansion, acquisition inorganic
FY28 revenue guided at INR4,000 crores driven by business strategy and expansion into new markets
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Marksans Pharma Limited and 4,900+ companies.
5-day free pass. No card required.